- Home
- OCGN vs EPIX Comparison
OCGN vs EPIX Comparison
Compare OCGN & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- EPIX
- Stock Information
- Founded
- OCGN 2013
- EPIX 2009
- Country
- OCGN United States
- EPIX Canada
- Employees
- OCGN N/A
- EPIX N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- OCGN Health Care
- EPIX Health Care
- Exchange
- OCGN Nasdaq
- EPIX Nasdaq
- Market Cap
- OCGN 252.4M
- EPIX 209.4M
- IPO Year
- OCGN N/A
- EPIX N/A
- Fundamental
- Price
- OCGN $0.91
- EPIX $1.83
- Analyst Decision
- OCGN Strong Buy
- EPIX Hold
- Analyst Count
- OCGN 3
- EPIX 4
- Target Price
- OCGN $5.67
- EPIX $9.50
- AVG Volume (30 Days)
- OCGN 4.3M
- EPIX 2.4M
- Earning Date
- OCGN 11-08-2024
- EPIX 12-10-2024
- Dividend Yield
- OCGN N/A
- EPIX N/A
- EPS Growth
- OCGN N/A
- EPIX N/A
- EPS
- OCGN N/A
- EPIX N/A
- Revenue
- OCGN $4,700,000.00
- EPIX N/A
- Revenue This Year
- OCGN N/A
- EPIX N/A
- Revenue Next Year
- OCGN N/A
- EPIX N/A
- P/E Ratio
- OCGN N/A
- EPIX N/A
- Revenue Growth
- OCGN N/A
- EPIX N/A
- 52 Week Low
- OCGN $0.36
- EPIX $1.40
- 52 Week High
- OCGN $2.11
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- OCGN 44.59
- EPIX 26.56
- Support Level
- OCGN $0.85
- EPIX $1.66
- Resistance Level
- OCGN $0.94
- EPIX $1.89
- Average True Range (ATR)
- OCGN 0.08
- EPIX 0.12
- MACD
- OCGN -0.01
- EPIX 0.08
- Stochastic Oscillator
- OCGN 19.64
- EPIX 79.31
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.